The approach most routinely used by pharmaceutical manufacturers includes a rotation of one or more disinfectants with a sporicidal agent. Regulatory agencies, including FDA and the European Medicines Agency (EMA), expect GMP manufacturers to implement a robust decontamination program for their cleanrooms. But, what if these solutions are a source of future contamination? It’s a problem in the pharmaceutical, biotech, and medical device industries, but one that’s easily remedied. Pharmaceutical facilities follow a strict microbial contamination control program for cleanrooms.
